Moderna: positive CHMP opinion on RSV

(CercleFinance.com) - Moderna announces that the CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorization (MA) in the EU for mRESVIA, an mRNA vaccine against respiratory syncytial virus (RSV).


This opinion concerns adults aged 60 and over against lower respiratory tract diseases caused by RSV infection. The European Commission must now adopt a decision on marketing authorization.

The recommendation is based on positive data from the ConquerRSV phase 3 clinical trial, which notably revealed a vaccine efficacy against RSV lower respiratory tract disease of 83.7% with a median follow-up of 3.7 months.

Copyright (c) 2024 CercleFinance.com. All rights reserved.